Loading
A phase 1 trial of Rivogenlecleucel run by Bellicum Pharmaceuticals, withdrawn before enrolling.
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies is a phase 1 interventional study registered as NCT02487459 by Bellicum Pharmaceuticals, started 2016-07. Conditions recorded: Hematologic Malignancies. Interventions recorded: BPX-501 and AP1903.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Shares Rivogenlecleucel, Bellicum Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/